- August 14, 2025STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the…
- August 5, 2025DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates STUTTGART, Germany I August 05, 2025 I La…
- August 5, 2025TSLP (thymic stromal lymphoprotein) is a clinically and commercially validated inflammatory target attracting numerous competitors STUTTGART, Germany I August 05,…
- August 5, 2025TL1A (TNF-like ligand 1A): the next big, clinically validated target for inflammatory bowel disease STUTTGART, Germany I August 05, 2025…
- August 5, 2025Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment STUTTGART, Germany…
- August 5, 2025Fibroblast Activation Protein: an emerging high-value theranostic target for delivery of payloads STUTTGART, Germany I August 05, 2025 I La…
- August 5, 2025Glypican-3 (GPC3): an emerging liver cancer target with opportunities for different effector mechanisms STUTTGART, Germany I August 05, 2025 I…
- August 5, 2025B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates STUTTGART, Germany I August 05, 2025 I La Merie…
- June 28, 2025STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an…
- March 9, 2025The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene…
